Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. Learn more about REPL stock here.

Aaron Tveit will return to Broadway’s Moulin Rouge! The Musical in his Tony-winning role of Christian from August 15 through ...

The smell of fresh-baked Greek pastries is filling the air in Wheeling this week as Grecian Fest returns for its 25th ...

Humans have cleared forests for thousands of years. Modern deforestation, however, has pushed the world’s forests ...

Rachel Reeves said growth was her “number one mission”. She has failed. New GDP figures show that the economy continues to ...

Grace Kim's amazing chip shot last year which eventually led to her winning the Evian Championship in a playoff. The Aussie was in a playoff with Jeeno Thitikul and dunked her second shot into the ...

The Advisory Committee meetings, a key regulatory step in U.S. drug and MedTech approvals, are making a comeback as the Food and Drug Administration seeks to revisit several controversial decisions ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

With a two-year target to move 50% of government sectors, services and operations to agentic artificial intelligence, the UAE is positioning autonomous systems as the next phase of digital government ...